ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis
NASDAQ:ORGO - Nasdaq - US68621F1021 - Common Stock - Currency: USD
Taking everything into account, ORGO scores 5 out of 10 in our fundamental rating. ORGO was compared to 558 industry peers in the Biotechnology industry. Both the profitability and the financial health of ORGO get a neutral evaluation. Nothing too spectacular is happening here. ORGO is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
ORGO had positive earnings in the past year.
In the past year ORGO had a positive cash flow from operations.
Of the past 5 years ORGO 4 years were profitable.
ORGO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -4.37%, ORGO belongs to the best of the industry, outperforming 87.63% of the companies in the same industry.
With an excellent Return On Equity value of -5.55%, ORGO belongs to the best of the industry, outperforming 89.96% of the companies in the same industry.
With an excellent Return On Invested Capital value of 1.02%, ORGO belongs to the best of the industry, outperforming 91.94% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 14.97%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -5.55% | ||
| ROIC | 1.02% |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
1.3 Margins
The Operating Margin of ORGO (1.13%) is better than 92.11% of its industry peers.
ORGO's Operating Margin has declined in the last couple of years.
ORGO has a better Gross Margin (75.85%) than 83.87% of its industry peers.
ORGO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.13% | ||
| PM (TTM) | N/A | ||
| GM | 75.85% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ORGO is destroying value.
Compared to 1 year ago, ORGO has less shares outstanding
Compared to 5 years ago, ORGO has more shares outstanding
Compared to 1 year ago, ORGO has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 4.70 indicates that ORGO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.70, ORGO is in the better half of the industry, outperforming 76.70% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that ORGO is not too dependend on debt financing.
ORGO has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: ORGO outperforms 47.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.7 |
ROIC/WACC0.1
WACC10.04%
2.3 Liquidity
ORGO has a Current Ratio of 4.12. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.12, ORGO perfoms like the industry average, outperforming 47.49% of the companies in the same industry.
ORGO has a Quick Ratio of 3.67. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO has a Quick ratio of 3.67. This is comparable to the rest of the industry: ORGO outperforms 44.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.67 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 125.00% over the past year.
The earnings per share for ORGO have been decreasing by -37.90% on average. This is quite bad
Looking at the last year, ORGO shows a small growth in Revenue. The Revenue has grown by 5.36% in the last year.
Measured over the past years, ORGO shows a quite strong growth in Revenue. The Revenue has been growing by 13.05% on average per year.
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
Revenue 1Y (TTM)5.36%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
3.2 Future
The Earnings Per Share is expected to grow by 24.29% on average over the next years. This is a very strong growth
Based on estimates for the next years, ORGO will show a small growth in Revenue. The Revenue will grow by 6.81% on average per year.
EPS Next Y-118%
EPS Next 2Y8.17%
EPS Next 3Y24.29%
EPS Next 5YN/A
Revenue Next Year2.62%
Revenue Next 2Y6.21%
Revenue Next 3Y6.81%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 48.56, the valuation of ORGO can be described as expensive.
Based on the Price/Earnings ratio, ORGO is valued cheaply inside the industry as 92.47% of the companies are valued more expensively.
ORGO is valuated expensively when we compare the Price/Earnings ratio to 27.50, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 21.97, which indicates a rather expensive current valuation of ORGO.
Based on the Price/Forward Earnings ratio, ORGO is valued cheaper than 92.11% of the companies in the same industry.
ORGO's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 36.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.56 | ||
| Fwd PE | 21.97 |
4.2 Price Multiples
94.80% of the companies in the same industry are more expensive than ORGO, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 19.74 |
4.3 Compensation for Growth
The decent profitability rating of ORGO may justify a higher PE ratio.
ORGO's earnings are expected to grow with 24.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.17%
EPS Next 3Y24.29%
5. Dividend
5.1 Amount
No dividends for ORGO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.37
+0.01 (+0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners51.78%
Inst Owner Change0%
Ins Owners31.29%
Ins Owner Change1.49%
Market Cap554.33M
Analysts84.44
Price Target6.38 (46%)
Short Float %15.09%
Short Ratio7.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)248.79%
Min EPS beat(2)-73%
Max EPS beat(2)570.59%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.47%
Min Revenue beat(2)-6.36%
Max Revenue beat(2)13.3%
Revenue beat(4)3
Avg Revenue beat(4)3.87%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)4
Avg Revenue beat(8)0.9%
Revenue beat(12)5
Avg Revenue beat(12)0.29%
Revenue beat(16)7
Avg Revenue beat(16)0.94%
PT rev (1m)0%
PT rev (3m)4.17%
EPS NQ rev (1m)-25%
EPS NQ rev (3m)-400%
EPS NY rev (1m)-180%
EPS NY rev (3m)-157.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.98%
Revenue NY rev (1m)-1.48%
Revenue NY rev (3m)-2.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.56 | ||
| Fwd PE | 21.97 | ||
| P/S | 1.21 | ||
| P/FCF | N/A | ||
| P/OCF | 124.99 | ||
| P/B | 1.51 | ||
| P/tB | 1.69 | ||
| EV/EBITDA | 19.74 |
EPS(TTM)0.09
EY2.06%
EPS(NY)0.2
Fwd EY4.55%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)0.03
OCFY0.8%
SpS3.62
BVpS2.9
TBVpS2.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -5.55% | ||
| ROCE | 1.29% | ||
| ROIC | 1.02% | ||
| ROICexc | 1.4% | ||
| ROICexgc | 1.63% | ||
| OM | 1.13% | ||
| PM (TTM) | N/A | ||
| GM | 75.85% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexcg growth 3Y-38.4%
ROICexcg growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score6
Asset Turnover0.98
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 65.96% | ||
| Cap/Sales | 2.49% | ||
| Interest Coverage | 1.44 | ||
| Cash Conversion | 19.68% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.67 | ||
| Altman-Z | 4.7 |
F-Score6
WACC10.04%
ROIC/WACC0.1
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
EPS Next Y-118%
EPS Next 2Y8.17%
EPS Next 3Y24.29%
EPS Next 5YN/A
Revenue 1Y (TTM)5.36%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
Revenue Next Year2.62%
Revenue Next 2Y6.21%
Revenue Next 3Y6.81%
Revenue Next 5YN/A
EBIT growth 1Y-59.06%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year510.28%
EBIT Next 3Y111.89%
EBIT Next 5YN/A
FCF growth 1Y57.36%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-75.86%
OCF growth 3Y-38.8%
OCF growth 5YN/A